tiprankstipranks
Circassia Pharmaceuticals PLC (CSSPF)
OTHER OTC:CSSPF

Circassia Pharmaceuticals (CSSPF) Stock Price & Analysis

8 Followers

CSSPF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $83.36
Previous Close$3.66
Volume19.00K
Average Volume (3M)19.00K
Market Cap
$341.15M
Enterprise Value$317.94M
Total Cash (Recent Filing)£19.40M
Total Debt (Recent Filing)£1.00M
Price to Earnings (P/E)115.5
Beta1.64
Sep 25, 2024
EPS EstimateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding422,120,630
10 Day Avg. Volume0
30 Day Avg. Volume19,000
Standard Deviation0.22
R-Squared0.06
Alpha0.00742
Financial Highlights & Ratios
Price to Book (P/B)5.52
Price to Sales (P/S)20.04
Price to Cash Flow (P/CF)27.00
P/FCF Ratio27.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%0.00%<0.01%100.00%
0.00%
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

CSSPF FAQ

What was Circassia Pharmaceuticals PLC’s price range in the past 12 months?
Circassia Pharmaceuticals PLC lowest stock price was $0.00 and its highest was $83.36 in the past 12 months.
    What is Circassia Pharmaceuticals PLC’s market cap?
    Currently, no data Available
    When is Circassia Pharmaceuticals PLC’s upcoming earnings report date?
    Circassia Pharmaceuticals PLC’s upcoming earnings report date is Sep 25, 2024 which is in 180 days.
      How were Circassia Pharmaceuticals PLC’s earnings last quarter?
      Circassia Pharmaceuticals PLC released its earnings results on Mar 26, 2024. The company reported $0.021 earnings per share for the quarter, beating the consensus estimate of N/A by $0.021.
        Is Circassia Pharmaceuticals PLC overvalued?
        According to Wall Street analysts Circassia Pharmaceuticals PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Circassia Pharmaceuticals PLC pay dividends?
          Circassia Pharmaceuticals PLC pays a Notavailable dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Circassia Pharmaceuticals PLC dividends here
            What is Circassia Pharmaceuticals PLC’s EPS estimate?
            Circassia Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Circassia Pharmaceuticals PLC have?
            Currently, no data Available
            What happened to Circassia Pharmaceuticals PLC’s price movement after its last earnings report?
            Circassia Pharmaceuticals PLC reported an EPS of $0.021 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -54.62%.
              Which hedge fund is a major shareholder of Circassia Pharmaceuticals PLC?
              Currently, no hedge funds are holding shares in CSSPF
              ---

              Circassia Pharmaceuticals Stock Smart Score

              6
              Neutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Positive
              20 days / 200 days
              Momentum
              45.03%
              12-Months-Change

              Fundamentals

              Return on Equity
              11.06%
              Trailing 12-Months
              Asset Growth
              -7.11%
              Trailing 12-Months

              Company Description

              Circassia Pharmaceuticals PLC

              Circassia Group PLC is a biotechnology company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of revenue from the US and also has a presence in EU, Asia Pacific and Rest of world.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Circassia Pharmaceuticals
              GlaxoSmithKline
              AstraZeneca
              Hikma Pharmaceuticals
              Futura Medical

              Best Analysts Covering CSSPF

              1 Year
              Unknown AnalystPeel Hunt
              Not Ranked
              1 Year Success Rate
              0/0 ratings generated profit
              0%
              1 Year Average Return
              0.00%
              reiterated a buy rating 6 months ago
              Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis